华兰生物: 关于公司控股子公司取得药物临床试验批准通知书的公告

Group 1 - The company, Hualan Biological Engineering Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of its "lyophilized type b Haemophilus influenzae conjugate vaccine" [1] - The vaccine aims to prevent invasive infections caused by type b Haemophilus influenzae, including meningitis, pneumonia, sepsis, cellulitis, arthritis, and epiglottitis [2] - The Hib vaccine is developed using purified Hib capsular polysaccharide combined with tetanus toxoid protein, and it is expected to induce an immune response against Hib [2] Group 2 - The company is also developing a combination vaccine based on the DTP (diphtheria, tetanus, and pertussis) vaccine, with the Hib vaccine as one of its components [2] - Following the approval of the clinical trial, the company must conduct clinical trials and obtain further approval from the National Medical Products Administration before the vaccine can be marketed [3] - The drug development process is lengthy and involves multiple stages, which may be affected by uncertainties [3]